Bolt Biotherapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
BOLT$6.54+2.5%Stored close · as of Nov 6, 2026
Contents
Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $10,810 | $9,244 |
| Short-term investments | 91,379 | 159,644 |
| Prepaid expenses and other current assets | 3,519 | 3,858 |
| Total current assets | 105,708 | 172,746 |
| Property and equipment, net | 4,957 | 6,453 |
| Operating lease right-of-use assets | 19,120 | 22,072 |
| Restricted cash | 1,765 | 1,565 |
| Long-term investments | 26,413 | 23,943 |
| Other assets | 1,821 | 1,028 |
| Total assets | $159,784 | $227,807 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $2,987 | $3,594 |
| Accrued expenses and other current liabilities | 12,486 | 15,140 |
| Deferred revenue | 2,201 | 1,993 |
| Operating lease liabilities | 2,782 | 2,391 |
| Total current liabilities | 20,456 | 23,118 |
| Operating lease liabilities, net of current portion | 17,437 | 20,220 |
| Deferred revenue, non-current | 9,107 | 12,921 |
| Other long-term liabilities | 43 | 42 |
| Total liabilities | 47,043 | 56,301 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.00001 par value, authorized shares—10,000,000 shares authorized at December 31, 2023 and 2022; zero shares issued and outstanding at December 31, 2023 and 2022 | — | — |
| Common stock, $0.00001 par value; 200,000,000 shares authorized at December 31, 2023 and 2022; 38,114,606 and 37,797,902 shares issued and outstanding at December 31, 2023 and 2022, respectively | 1 | — |
| Additional paid-in capital | 476,988 | 467,513 |
| Accumulated other comprehensive gain (loss) | 37 | (919) |
| Accumulated deficit | (364,285) | (295,088) |
| Total stockholders' equity | 112,741 | 171,506 |
| Total liabilities, convertible preferred stock, and stockholders' equity | $159,784 | $227,807 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.